Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE
  • entries
    84
  • comments
    0
  • views
    134

The antibody discovery services and platforms market is projected to grow at an annualized rate of ~10%, till 2030


Narender

3 views

Roots Analysis has done a detailed study on Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 450+ page report, which features 120+ figures and 140+ tables, please visit this link

 

Key Market Insights

§  Over 80 companies are offering antibody discovery services; of these, more than 75 players claim to offer services related to hit generation.

§  Nearly 180 innovative technology platforms have been developed by numerous firms for the purpose of antibody discovery.

§  Majority of stakeholders in the competitive market landscape are small / mid-sized firms, catering to the needs of a diverse clientele.

§  In order to get an edge over their competitors in the industry, companies have established their presence in different regions across the globe.

§  The rising interest in this field is reflected in the number of partnerships inked in the recent past, involving both international and indigenous stakeholders, and focused on antibody discovery for diverse range of indications.

§  Efforts of the players in the field of antibody discovery have garnered significant interest of several venture capital investors.

§  The antibody discovery services market is expected to witness growth at a CAGR of ~10%; the anticipated opportunity is likely to be distributed across various steps involved in antibody discovery, antibody discovery method, nature of antibody generated and geographies.

§  The market for antibody discovery platforms is currently being driven by the revenues from the licensing deals; it is anticipated to reach USD 5.9 billion by 2030.

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-discovery-services-and-platforms/213.html

                                                                                                               

Table of Contents

 

1.         PREFACE

1.1.        Scope of the Report

1.2.        Research Methodology

1.3.        Chapter Outlines

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

3.1.       Chapter Overview

3.2.       Structure of Antibodies

3.3.       History of Development

3.4.       Antibody Isotypes

3.5.       Mechanism of Action of Antibodies

3.6.       Classification of Antibodies

3.6.1.    Monoclonal Antibodies

3.6.2.    Polyclonal Antibodies

3.6.3.    Bispecific Antibodies

3.7.       Applications of Antibodies

 

 

 

Press Release: Variation 2 (Format 3)

 

4.         ANTIBODY DISCOVERY PROCESS AND METHODS

4.1.       Chapter Overview

4.2.       Antibody Discovery Process

4.2.1.    Target Selection and Validation

4.2.2.    Hit Generation

4.2.3.    Lead Selection

4.2.4.    Lead Optimization

4.2.4.1. Humanization

4.2.4.2. Affinity Maturation

4.2.4.3. Fc Engineering

4.2.5.    Lead Characterization

4.2.6.    Candidate Selection

 

4.3.       Antibody Discovery Methods

4.3.1.    Hybridoma Method

4.3.2.    In vitro Display Method

4.3.2.1. Phage Display

4.3.2.2. Yeast Display

4.3.2.3. Ribosomal Display

4.3.3.    Transgenic Animal-Based Method

4.3.4.    Single B Cell-Based Method

4.3.5.    Advantages and Disadvantages of Existing Antibody Discovery Techniques

 

4.4.       Evolution of Monoclonal Antibodies

4.4.1.    Fully Human Monoclonal Antibodies

 

5.         ANTIBODY DISCOVERY SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE

5.1.       Chapter Overview

5.2.       Antibody Discovery Service Providers: List of Industry Players

5.2.1.    Analysis by Year of Establishment

5.2.2.    Analysis by Company Size

5.2.3.    Analysis by Location of Headquarters

5.2.4.    Analysis by Type of Service Offered

5.2.5.    Analysis by Type of Antibody Discovery Method

5.2.6.    Grid Representation: Analysis by Type of Service Offered, Type of Antibody Discovery Method and Company Size

5.2.7.    Analysis by Animal Model Used

5.2.8.    Analysis by Type of Antibody Discovered

5.2.9.    Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered

5.2.10.  Analysis by Purpose of Antibody Discovery

5.2.11.  Analysis by Type of Antibody Discovery Method and Purpose of Antibody Discovery

 

6.         COMPANY COMPETITIVENESS ANALYSIS

6.1.       Chapter Overview

6.2.       Methodology

6.3.       Key Parameters

6.4.       Competitiveness Analysis: Antibody Discovery Service Providers

6.4.1.    Antibody Discovery Service Providers based in North America

6.4.2.    Antibody Discovery Service Providers based in Europe

6.4.3.    Antibody Discovery Service Providers based in Asia Pacific

 

7.         COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS

7.1.       Chapter Overview

7.2.       Antibody Discovery Service Providers in North America

7.2.1.    Abwiz Bio

7.2.1.1. Company Overview

Press Release: Variation 2 (Format 3)

 

7.2.1.2. Antibody Discovery Services

7.2.1.3. Recent Developments and Future Outlook

 

7.2.2.    Aragen Bioscience (A GVK BIO Company)

7.2.2.1. Company Overview

7.2.2.2. Antibody Discovery Services

7.2.2.3. Recent Developments and Future Outlook

 

7.2.3.    Distributed Bio

7.2.3.1. Company Overview

7.2.3.2. Antibody Discovery Services

7.2.3.3. Recent Developments and Future Outlook

 

7.2.4.    Integral Molecular

7.2.4.1. Company Overview

7.2.4.2. Antibody Discovery Services

7.2.4.3. Recent Developments and Future Outlook

 

7.2.5.    LakePharma

7.2.5.1. Company Overview

7.2.5.2. Antibody Discovery Services

7.2.5.3. Recent Developments and Future Outlook

 

7.3.       Antibody Discovery Service Providers in Europe

7.3.1.    Abzena

7.3.1.1. Company Overview

7.3.1.2. Financial Information

7.3.1.3. Antibody Discovery Services

7.3.1.4. Recent Developments and Future Outlook

 

7.3.2.    ImmunoPrecise Antibodies

7.3.2.1. Company Overview

7.3.2.2. Financial Information

7.3.2.3. Antibody Discovery Services

7.3.2.4. Recent Developments and Future Outlook

 

7.3.3.    PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)

7.3.3.1. Company Overview

7.3.3.2. Antibody Discovery Services

7.3.3.3. Recent Developments and Future Outlook

 

7.4.       Antibody Discovery Service Providers in Asia-Pacific

7.4.1.    ChemPartner

7.4.1.1. Company Overview

7.4.1.2. Antibody Discovery Services

7.4.1.3. Recent Developments and Future Outlook

 

7.4.2.    Viva Biotech

7.4.2.1. Company Overview

7.4.2.2. Financial Information

7.4.2.3. Antibody Discovery Services

7.4.2.4. Recent Developments and Future Outlook

 

7.4.3.    WuXi Biologics

7.4.3.1. Company Overview

7.4.3.2. Financial Information

Press Release: Variation 2 (Format 3)

 

7.4.3.3. Antibody Discovery Services

7.4.3.4. Recent Developments and Future Outlook

 

8.         ANTIBODY DISCOVERY TECHNOLOGIES: CURRENT MARKET LANDSCAPE

8.1.       Chapter Overview

8.2.       Antibody Discovery Platform Providers: List of Industry Players

8.2.1.    Analysis by Year of Establishment

8.2.2.    Analysis by Company Size

8.2.3.    Analysis by Location of Headquarters

8.2.4.    Analysis by Type of Antibody Discovered

8.3.       Antibody Discovery: List of Technologies and Platforms

8.3.1.    Analysis by Type of Antibody Discovery Method

8.3.2.    Analysis by Type of Antibody Discovery Method and Location of Headquarters

8.3.3.    Analysis by Animal Model Used

8.3.4.    Analysis by Patent Availability

 

9.         TECHNOLOGY COMPETITIVENESS ANALYSIS

9.1.       Chapter Overview

9.2.       Methodology

9.3.       Key Parameters

9.4.       Technology Competitiveness Analysis: Antibody Discovery Platforms

9.4.1.    Competitiveness Analysis: Library Based Antibody Discovery Platforms

9.4.2.    Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms

9.4.3.    Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms

9.4.4.    Competitiveness Analysis: Other Antibody Discovery Platforms

 

10.        COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS

10.1.     Chapter Overview

10.2.     ImmunoPrecise Antibodies

10.2.1.  Company Overview

10.2.2.  Financial Information

10.2.3.  Portfolio of Antibody Discovery Platforms

10.2.3.1. Abthena™

10.2.3.2. B cell Select™

10.2.3.3. DeepDisplay™

10.2.3.4. ModiFuse™

10.2.3.5. ModiPhage™

10.2.3.6. ModiSelect™

10.2.3.7. ModiTune™

10.2.4.   Recent Developments and Future Outlook

 

10.3.     Harbour BioMed

10.3.1.  Company Overview

10.3.2.  Portfolio of Antibody Discovery Platforms

10.3.2.1. H2L2 Platform

10.3.2.2. HCAb Platform

10.3.3.   Recent Developments and Future Outlook

 

10.4.     Kymab

10.4.1.  Company Overview

10.4.2.  Portfolio of Antibody Discovery Platforms

10.4.2.1. Kymouse™

10.4.2.2. IntelliSelect®

10.4.3.   Recent Developments and Future Outlook

 

10.5.     Ligand Pharmaceuticals

Press Release: Variation 2 (Format 3)

 

10.5.1.  Company Overview

10.5.2.  Financial Information

10.5.3.  Portfolio of Antibody Discovery Platforms

10.5.3.1. OmniAb®

10.5.3.1.1. OmniChicken®

10.5.3.1.2. OmniClic™

10.5.3.1.3. OmniFlic®

10.5.3.1.4. OmniMouse®

10.5.3.1.5. OmniRat®

10.5.4.  Recent Developments and Future Outlook

 

10.6.     MorphoSys

10.6.1.  Company Overview

10.6.2.  Financial Information

10.6.3.  Portfolio of Antibody Discovery Platforms

10.6.3.1. arYla® Technology

10.6.3.2. HuCAL® Technology

10.6.3.3. Ylanthia® Technology

10.6.4.  Recent Developments and Future Outlook

 

11.        REGIONAL CAPABILITY ANALYSIS

11.1.     Chapter Overview

11.2.     Key Assumptions and Methodology

11.3.     Regional Capability Analysis: Antibody Discovery Service Providers

11.3.1.  Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in North America

11.3.2.  Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in Europe

11.3.3.  Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in Asia-Pacific

 

11.4.     Regional Capability Analysis: Antibody Discovery Platform Providers

11.4.1.  Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in North America

11.4.2.  Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in Europe

11.4.3.  Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in Asia-Pacific

 

11.5.     Concluding Remarks

 

12.        PARTNERSHIPS AND COLLABORATIONS

12.1.     Chapter Overview

12.2.     Partnership Models

12.3.     List of Partnerships and Collaborations

12.3.1.  Analysis by Year of Partnership

12.3.2.  Analysis by Type of Partnership

12.3.3.  Analysis by the Type of Company (Service / Platform Providers)

12.3.4.  Analysis by Type of Antibody Discovered

12.3.5.  Analysis by Year of Partnership and Type of Partner

12.3.6.  Analysis by Type of Partnership and Type of Partner

12.3.7.  Most Active Players: Analysis by Number of Partnerships

12.3.8.  Most Popular Technologies: Analysis by Number of Partnerships

12.3.9.  Regional Analysis

12.3.9.1. Intercontinental and Intracontinental Agreements

 

Press Release: Variation 2 (Format 3)

 

13.        FUNDING AND INVESTMENT ANALYSIS

13.1.     Chapter Overview

13.2.     Types of Funding

13.3.     Antibody Discovery Service and Platform Providers: Funding and Investment Analysis

13.3.1.  Analysis by Number of Instances

13.3.2.  Analysis by Amount Invested

13.3.3.  Analysis by Type of Funding

13.3.4.  Most Active Players: Analysis by Amount Invested

13.3.5.  Most Active Investors: Analysis by Number of Funding Instances

13.3.6.  Regional Analysis by Amount Invested

 

13.4.     Concluding Remarks

 

14.        ANTIBODY DISCOVERY SERVICES: MARKET FORECAST

14.1.     Chapter Overview

14.2.     Forecast Methodology

14.3.     Global Antibody Discovery Services Market, 2020-2030

14.4.     Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2020-2030

14.4.1.  Antibody Discovery Services Market for Antigen Designing, 2020-2030

14.4.2.  Antibody Discovery Services Market for Hit Generation, 2020-2030

14.4.3.  Antibody Discovery Services Market for Lead Selection, 2020-2030

14.4.4.  Antibody Discovery Services Market for Lead Optimization, 2020-2030

14.4.5.  Antibody Discovery Services Market for Lead Characterization, 2020-2030

14.5.     Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2020-2030

14.5.1.  Antibody Discovery Services Market for Phage Display, 2020-2030

14.5.2.  Antibody Discovery Services Market for Yeast Display, 2020-2030

14.5.3.  Antibody Discovery Services Market for Hybridoma Method, 2020-2030

14.5.4.  Antibody Discovery Services Market for Transgenic Animal Based Method, 2020-2030

14.5.5.  Antibody Discovery Services Market for Single Cell Based Method, 2020-2030

14.5.6.  Antibody Discovery Services Market for Other Methods, 2020-2030

14.6.     Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2020-2030

14.6.1.  Antibody Discovery Services Market for Humanized Antibodies, 2020-2030

14.6.2.  Antibody Discovery Services Market for Human Antibodies, 2020-2030

14.6.3.  Antibody Discovery Services Market for Chimeric Antibodies, 2020-2030

14.6.4.  Antibody Discovery Services Market for Murine Antibodies, 2020-2030

14.7.     Global Antibody Discovery Services Market: Distribution by Region, 2020-2030

14.7.1.  Antibody Discovery Services Market in North America, 2020-2030

14.7.2.  Antibody Discovery Services Market in Europe, 2020-2030

14.7.3.  Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2020-2030

14.7.4.  Antibody Discovery Services: Market Attractiveness Analysis by Region

 

15.        ANTIBODY DISCOVERY TECHNOLOGIES: MARKET FORECAST

15.1.     Chapter Overview

15.2.     Key Assumptions

15.3.     Forecast Methodology

15.4.     Global Antibody Discovery Platforms Market, 2020-2030

15.5.     Global Antibody Discovery Platforms Market: Distribution by Region, 2020-2030

15.5.1.  Antibody Discovery Platforms Market in North America, 2020-2030

15.5.2.  Antibody Discovery Platforms Market in Europe, 2020-2030

15.5.3.  Antibody Discovery Platforms Market in Asia-Pacific, 2020-2030

 

16.        CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES

16.1.     Chapter Overview

Press Release: Variation 2 (Format 3)

 

16.2.     Humira® (Adalimumab)

16.2.1.  Drug Overview

16.2.2.  Discovery Process and Method

16.2.3.  Historical Sales

 

16.3.     Keytruda® (Pembrolizumab)

16.3.1.  Drug Overview

16.3.2.  Discovery Process and Method

16.3.3.  Historical Sales

 

16.4.     Herceptin® (Trastuzumab)

16.4.1.  Drug Overview

16.4.2.  Discovery Process and Method

16.4.3.  Historical Sales

 

16.5.     Avastin® (Bevacizumab)

16.5.1.  Drug Overview

16.5.2.  Discovery Process and Method

16.5.3.  Historical Sales

 

16.6.     Rituxan® (Rituximab)

16.6.1.  Drug Overview

16.6.2.  Discovery Process and Method

16.6.3.  Historical Sales

 

17.        CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION

17.1.     Importance of Antibody Humanization and Affinity Maturation

17.2.     Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape

17.3.     Antibody Humanization: Publication Analysis

17.3.1.  Publication Analysis: Year-Wise Trend

17.3.2.  Publication Analysis: Key Journals

17.3.3.  Publication Analysis: Distribution by Animal Model Used

17.3.4.  Publication Analysis: Distribution by Method Used for Humanization

17.4.     Antibody Humanization Service and Platform Providers: SWOT Analysis

 

18.        FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY

18.1.     Chapter Overview

18.2.     Anticipated Shift from Monoclonal Antibodies to Other Novel Formats

18.3.     Technological Advancements to Overhaul Conventional Antibody Discovery Processes

18.4.     Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies

18.5.     Rising Demand for Antibody-based Treatment Options across Non-Oncology Indications

18.6.     Growing Market Opportunities in the Asia-Pacific Region

18.7.     Expected Increase in Number of Collaborations and Licensing Activity

18.8.     Concluding Remarks

 

19.        EXECUTIVE INSIGHTS

19.1.     Chapter Overview

 

19.2.     Abveris Antibody

19.2.1.  Company Snapshot

19.2.2.  Tracey Mullen, Chief Executive Officer (Q2 2020)

 

19.3.     Nidus Biosciences

19.3.1.  Company Snapshot

19.3.2.  Lisa Delouise, Founder and Chief Technology Officer (Q1 2020)

Press Release: Variation 2 (Format 3)

 

19.4.     AvantGen

19.4.1.  Company Snapshot

19.4.2.  Mark Kubik, Chief Business Officer (Q1 2020)

 

19.5.     Single Cell Technology

19.5.1.  Company Snapshot

19.5.2.  Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)

 

19.6.     Distributed Bio

19.6.1.  Company Snapshot

19.6.2.  Giles Day, Co-Founder and Chief Executive Officer (Q2 2018)

 

19.7.     AbCellera

19.7.1.  Company Snapshot

19.7.2.  Kevin Heyries, Co-Founder and Lead of Business Development Strategy (Q2 2018)

 

19.8.     AbGenics Life Sciences

19.8.1.  Company Snapshot

19.8.2.  Sanjiban K Banerjee, Director (Q2 2018)

 

19.9.     CDI Laboratories

19.9.1.  Company Snapshot

19.9.2.  Ignacio Pino, Chief Executive Officer and President (Q2 2017)

 

19.10.   AP Biosciences

19.10.1. Company Snapshot

19.10.2. Jeng Her, Chief Executive Officer (Q2 2017)

 

19.11.   YUMAB

19.11.1. Company Snapshot

19.11.2. Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)

 

19.12.   Antibody Solutions

19.12.1. Company Snapshot

19.12.2. Debra Valsamis, Business Development Associate (Q2 2017)

 

19.13.   Ligand Pharmaceuticals

19.13.1. Company Snapshot

19.13.2. Christel Iffland, Vice President (Q2 2017)

 

19.14.   LakePharma

19.14.1. Company Snapshot

19.14.2. Aaron Sato, Chief Scientific Officer (Q2 2017)

 

20.        CONCLUDING REMARKS

20.1.     Chapter Overview

20.2.     Key Takeaways

 

21.        APPENDIX 1: TABULATED DATA

 

22.        APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

0 Comments


Recommended Comments

There are no comments to display.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
  • Create New...